Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Vabysmo
Vabysmo
Vabysmo crosses $4B mark, Polivy joins blockbuster club as Roche preps for key readouts
Fierce Pharma
Thu, 01/30/25 - 11:30 pm
Roche
Polivy
Vabysmo
earnings
Roche's Vabysmo shows potential to treat eye disorder common in Asia
Fierce Pharma
Fri, 11/22/24 - 11:19 am
Roche
Vabysmo
age-related macular degeneration
Asia
Roche reports topline data from trial of Vabysmo for diabetic macular edema
Clinical Trials Arena
Mon, 10/21/24 - 09:44 am
Roche
Vabysmo
diabetic macular edema
Roche lifts 2024 profit guidance on strong drug sales
Reuters
Thu, 07/25/24 - 11:27 am
Roche
earnings
Vabysmo
Roche reports long-term data from diabetic macular edema treatment trial
Clinical Trials Arena
Thu, 07/18/24 - 11:25 am
Roche
clinical trials
Vabysmo
diabetic macular edema
Roche scores FDA nod for prefilled syringe version of Vabysmo, easing its administration
Fierce Pharma
Mon, 07/8/24 - 11:47 am
Roche
Vabysmo
FDA
Big Pharma’s most improved drugs: a new generation of blockbusters
Pharma Voice
Tue, 05/14/24 - 11:34 am
Big Pharma
Eli Lilly
Mounjaro
Novo Nordisk
Wegovy
JNJ
Tecvayli
Merck
Vaxneuvance
AbbVie
Qulipta
AstraZeneca
Saphnelo
Novartis
Leqvio
Roche
Genentech
Vabysmo
Amgen
Evenity
Pfizer
Vyndaqel
Roche reports data from Phase III retinal vein occlusion therapy trials
Clinical Trials Arena
Thu, 02/1/24 - 11:15 am
Roche
Vabysmo
macular edema
central retinal vein occlusion
Regeneron touts launch of high-dose Eylea in battle with Roche's Vabysmo
Fierce Pharma
Thu, 11/2/23 - 11:48 am
Regeneron
Eylea
Roche
Vabysmo
FDA Approves Genentech’s Vabysmo for the Treatment of Retinal Vein Occlusion (RVO)
BioSpace
Fri, 10/27/23 - 11:34 am
Vabysmo
Genentech
Roche
retinal vein occlusion
Roche's Q3 sales down 3% on currency headwinds, drop in COVID sales
Reuters
Thu, 10/19/23 - 10:03 am
Roche
earnings
Vabysmo
Amid Eylea showdown, Roche's Vabysmo shows durability in retinal vein occlusion
Fierce Pharma
Wed, 10/11/23 - 10:13 am
Roche
retinal vein occlusion
Vabysmo
Roche’s Vabysmo reports positive outcomes in multiple eye diseases
Clinical Trials Arena
Thu, 07/20/23 - 10:04 am
Roche
Vabysmo
diabetic macular edema
wet age-related macular degeneration
FDA Accepts Application for Genentech’s Vabysmo for the Treatment of Retinal Vein Occlusion (RVO)
BioSpace
Tue, 05/9/23 - 12:27 pm
Roche
Genentech
FDA
Vabysmo
macular edema
retinal vein occlusion
Roche’s new eye drug pressures Eylea with strong launch
BioPharma Dive
Wed, 04/26/23 - 05:44 pm
Roche
Vabysmo
Eylea
earnings
Regeneron
Genentech opens up eye patients’ world with Vabysmo
Medical Marketing and Media
Thu, 04/20/23 - 11:40 pm
Genentech
Vabysmo
wet age-related macular degeneration
DTC ads
Trials cue up new use for Roche's eye disease drug Vabysmo
Pharmaphorum
Fri, 02/10/23 - 10:24 am
Roche
Vabysmo
clinical trials
retinal vein occlusion
A year of two halves for US approvals
EP Vantage
Thu, 01/19/23 - 09:38 am
FDA
drug approvals
Mounjaro
Eli Lilly
Vabysmo
Roche
Opdualag
Bristol Myers Squibb
Carvykti
JNJ
Vtama
Roivant
Pluvicto
Novartis
Roche's Vabysmo lands clinical counterpunch in ophthalmology brawl with Eylea
Fierce Pharma
Thu, 10/27/22 - 11:02 am
Roche
Genentech
Vabysmo
bispecific antibodies
Eylea
Look out, Regeneron. As the threat from Roche's Vabysmo grows, one team of analysts slashes its Eylea sales estimate
Fierce Pharma
Mon, 07/25/22 - 10:00 pm
Regeneron
Eylea
Roche
Vabysmo
Pages
1
2
next ›
last »